Related Experiment Video

Updated: Jul 9, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K

Gliptin-induced bullous pemphigoid

Maria Ganeva, Tanya Gancheva, Karen Manuelyan

    International Journal of Clinical Pharmacology and Therapeutics
    |November 30, 2023
    PubMed
    Summary

    Drug-induced bullous pemphigoid (DIBP) can be triggered by dipeptidyl peptidase-4 (DPP-4) inhibitors like linagliptin. Careful drug assessment and multidisciplinary care are crucial for managing DIBP in elderly patients.

    More Related Videos

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis10:27

    Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

    Published on: December 15, 2011

    24.6K
    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    4.4K

    Related Concept Videos

    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    190